Two pieces examining metabolic dysfunction‑associated steatotic liver disease (MASLD) in Indian cohorts highlight rising prevalence and heterogeneous demographic risk. A letter and a mapping study synthesize MAP Study data and regional analyses to flag population‑specific drivers. Researchers Bose, Sridharan, Gupta and others call for tailored screening and public‑health responses given differing obesity, diabetes and genetic risk profiles across Indian regions. The work stresses local data to guide resource allocation and clinical guidelines. For drug developers and public‑health planners: these analyses identify sizeable at‑risk populations for MASLD therapeutics and preventive interventions, and they underscore the need for region‑specific natural history data to design trials.